Aster DM Healthcare Ltd up by 4.89% - Traders Corners | Espresso

EspressoLogy

Espresso Shot of the Day - Aster DM Healthcare Ltd up by 4.89 percent

July 26, 2022
Espresso Shot of the Day - Aster DM Healthcare Ltd up by 4.89 percent

ASTER DM HEALTHCARE LTD 230.65  (+4.89%)  BSE –  INE914M01019 | 26th July 2022

https://www.myespresso.com/images/Binge-graph-image_Aster-DM-Healthcare-Ltd1-202207261845283561544.jpg

From a single medical centre to becoming a performance-driven healthcare enterprise spread across more than 366 medical establishments, including 27 hospitals, 115 clinics and 223 pharmacies in 7 countries and growing, Aster DM Healthcare has transitioned into a leading healthcare authority across the Middle East and India. Currently one of the largest and fastest growing conglomerates in the MENA region, Aster DM Healthcare covers the full spectrum of healthcare services. The medical behemoth now has an expansive portfolio that includes hospitals and clinics, pharmacies, diagnostic centres, educational institutions, healthcare management and healthcare support systems. Headquartered in Dubai, the Aster DM network now encompasses more than 19,657 employees( Doctors, Nurses, and Others) with JCI accredited clinics and diagnostic centres.


Recent Drivers

  • Aster Innovation and Research Centre in partnership with Intel Corporation, and CARPL on June 29, 2022, announced the launch of a ‘Secure Federated Learning Platform’.  The collaboration will boost innovation in areas such as drug discovery, diagnosis, genomics, and predictive healthcare. It will also allow clinical trials to access relevant data sets in a secure and distributed manner, the company said.
  • Aster DM Healthcare announced the launch of its latest integrated advanced healthcare facility at Trivandrum in Kerala on June 17, 2022. The company's investment will be to the tune of Rs.500 crores+ for the entire project, with the first phase having a capacity of 350 beds which is expected to be operational by FY26.
  • The company approved and recommended the re-appointment of Dr Azad Moopen as Managing Director of the Company for a term of three years with effect from April 15, 2023, for approval of the shareholders at the ensuing Annual General Meeting subject to the approval of Central Government.
  • The company reported a quarterly net Profit of Rs.226.27 crores in March 2022, up 114.7% from Rs.105.39 crores in March 2021 on May 25th
  • The company reported Net Sales of Rs 2,727.79 crores in March 2022, up 14.09% from Rs.2,390.88 crores in March 2021 on May 25, 2022.
(Sources: BSE, Business Standard,Money control)


Technical Force*

  • S&P BSE Small Cap month till date gain by 5.58%
  • 3 months avg. NSE volume: 665,214
  • Quantity traded: 80,884 | Deliverable Quantity: 21,944 (27.13 %)
  • The stock price jumped by more than 50% from a one-year low level: 558.60 (August 10th,2021)
  • Daily RSI (14) is at overbought territory today
  • 52-week-high: 237.55 | 52-week-low: 148.70


Key Pivot (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

334.75

286.00

230.05

181.30

125.35

76.60

20.65

-

Fibonacci Pivot

286.00

246.00

221.30

205.38

181.30

157.22

141.30

116.60

76.60


Today’s Close

230.65

SMA

BSE

10 DAY

216.82

20 DAY

199.74

50 DAY

189.90

200 DAY

187.71


Some Key Ratios (Source: BSE)

Market Cap: 11,521.27 Crores

PE:  127.76

OPM%: 33.89

ROE%:  3.05

Promoters holding%: 37.88

Prev. Close:  219.90


https://www.myespresso.com/images/espresso_shot_blog_credit_image%20WD-202206271809546799546.jpg

Chart and Technical Force data from the Binge desktop app

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan Comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comrade Private Limited is under no obligation to update the information in this document from time-to-time.

Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.